Emirhan Harbi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Emirhan Harbi has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Michael Aschner
Albert Einstein College of Medicine
9 shared publicationsChristopher E. Mason
Weill Cornell Medicine
3 shared publicationsHamza Ugur Bozbey
Istanbul University
3 shared publicationsAytug Altundag
Biruni University
2 shared publications- Christopher E. Mason
Department of Physiology and Biophysics, Weill Cornell Medicine, New York, USA
2 shared publications Didem Tastekin
Department of Clinical Oncology, Institute of Oncology, Istanbul University
2 shared publications
Latest Publications
- Open Access
- 21 October 2026
- Published by Springer Nature in Research Square
Functional and MRI improvement followed by a mixed trajectory during cannabinoid-terpenoid exposure in glioblastoma: a case report
Background: Glioblastoma has limited salvage options, while viable tumour, treatment injury, postoperative change, oedema and corticosteroid effects may produce overlapping clinical and magnetic resonance imaging (MRI) findings. Materials and Methods: Clinical records, serial MRI examinations and signed radiology reports were reviewed descriptively for a patient with IDH-wildtype, MGMT-promoter-methylated glioblastoma. The exposure history and contemporaneously documented neurological findings were aligned with seven MRI time points. No blinded central review, standardised volumetry or formal RANO 2.0 adjudication was performed. Results: After two operations, radiotherapy, concomitant temozolomide and three adjuvant cycles, serial MRI documented progression before April 2025. During a non-standard exposure state comprising intranasal perillyl alcohol and alpha-bisabolol, individualised cannabinoids and docosahexaenoic acid/medium-chain triglyceride oil, with dexamethasone fixed at 2 mg/day, hemiplegia/KPS 50 improved to hemiparesis with regained walking/KPS 80, coinciding with reduced enhancement. Later MRI showed increasing right temporal and cerebellar enhancement, including a new contralateral cerebellar focus, despite substantially stable postoperative cavity and T2/FLAIR extent. June 2026 lesion perfusion curves were low-amplitude without pathological hyperperfusion. The patient subsequently died after an overall survival of 45 months. Conclusions: This uncontrolled case documents early functional and radiological improvement on a stable corticosteroid background, followed by an anatomically progressive but biologically indeterminate trajectory. It does not establish treatment causality, survival benefit, formal tumour response or component-specific efficacy; mixed viable tumour and treatment effect or radiation necrosis could not be excluded. Although this single case does not establish a verified benefit the observed overall survival reached a time span of extraordinarily 45 months.
- 21 October 2026
- Published by Springer Nature in Research Square
Open AccessFunctional and MRI improvement followed by a mixed trajectory during cannabinoid-terpenoid exposure in glioblastoma: a case report
Background: Glioblastoma has limited salvage options, while viable tumour, treatment injury, postoperative change, oedema and corticosteroid effects may produce overlapping clinical and magnetic resonance imaging (MRI) findings. Materials and Methods: Clinical records, serial MRI examinations and signed radiology reports were reviewed descriptively for a patient with IDH-wildtype, MGMT-promoter-methylated glioblastoma. The exposure history and contemporaneously documented neurological findings were aligned with seven MRI time points. No blinded central review, standardised volumetry or formal RANO 2.0 adjudication was performed. Results: After two operations, radiotherapy, concomitant temozolomide and three adjuvant cycles, serial MRI documented progression before April 2025. During a non-standard exposure state comprising intranasal perillyl alcohol and alpha-bisabolol, individualised cannabinoids and docosahexaenoic acid/medium-chain triglyceride oil, with dexamethasone fixed at 2 mg/day, hemiplegia/KPS 50 improved to hemiparesis with regained walking/KPS 80, coinciding with reduced enhancement. Later MRI showed increasing right temporal and cerebellar enhancement, including a new contralateral cerebellar focus, despite substantially stable postoperative cavity and T2/FLAIR extent. June 2026 lesion perfusion curves were low-amplitude without pathological hyperperfusion. The patient subsequently died after an overall survival of 45 months. Conclusions: This uncontrolled case documents early functional and radiological improvement on a stable corticosteroid background, followed by an anatomically progressive but biologically indeterminate trajectory. It does not establish treatment causality, survival benefit, formal tumour response or component-specific efficacy; mixed viable tumour and treatment effect or radiation necrosis could not be excluded. Although this single case does not establish a verified benefit the observed overall survival reached a time span of extraordinarily 45 months.
- 10 August 2026
- Published by Wiley in Journal of Neuroscience Research
- Vol. 104 (8) , e70147
The Endoterpenoid System: A Membrane‐Based Logic Framework for Integrating Cannabinoid, Olfactory, and Lipid‐Sensitive Receptor Crosstalk
The Endoterpenoid System (ETS) is a proposed new membrane‐based framework that ensembles classical endocannabinoid signaling (ECS) with ectopically expressed olfactory GPCRs, ion channels, and microbially derived terpenoids. Integrated with this model is the proposed endoterpenoidome (eTBome) machine: a chemically diverse pool of endogenous cannabinoids, dietary terpenoids, and microbial metabolites whose lipophilicity drives partitioning into cholesterol‐rich lipid rafts. Within these nanoscale microdomains, ETS components undergo co‐localization and co‐expression, enabling receptor heteromerization and β‐arrestin‐scaffolded signalosomes that facilitate dynamic crosstalk and emergent responses such as bistable apoptotic switches and context specific modulation of Gᵢ/o, Gₛ/olf, and Gq pathways. We detail molecular mechanisms underpinning ETS behavior, including lipid mediated allostery, scaffold protein recruitment, and lateral diffusion effects, and highlight the gut microbiota as pivotal architects of the eTBome through terpene synthase‐driven production of bioactive ligands. Germ free and antibiotic treated animal models underscore the dependence of ETS ligand pools and receptor distributions on microbial colonization. This article proposes key avenues for experimental validation, including high resolution structural studies of CB‐OR heteromers, quantitative lipidomic mapping of eTBome distributions, live cell super resolution imaging of receptor nanoclusters, and gnotobiotic manipulations of microbial terpene synthesis. By introducing them as proposals to the scientific community and by integrating ECS/eCBome biology with olfactory receptor (OR) and microbial metabolite research, the ETS/eTBome concept offers a cohesive hypothesis for lipid‐driven GPCR crosstalk and indicated non‐standard targets for therapeutic modulation in cancer, neuroinflammation, and metabolic disorders.
- 10 August 2026
- Published by Wiley in Journal of Neuroscience Research
- Vol. 104 (8) , e70147
The Endoterpenoid System: A Membrane‐Based Logic Framework for Integrating Cannabinoid, Olfactory, and Lipid‐Sensitive Receptor Crosstalk
The Endoterpenoid System (ETS) is a proposed new membrane‐based framework that ensembles classical endocannabinoid signaling (ECS) with ectopically expressed olfactory GPCRs, ion channels, and microbially derived terpenoids. Integrated with this model is the proposed endoterpenoidome (eTBome) machine: a chemically diverse pool of endogenous cannabinoids, dietary terpenoids, and microbial metabolites whose lipophilicity drives partitioning into cholesterol‐rich lipid rafts. Within these nanoscale microdomains, ETS components undergo co‐localization and co‐expression, enabling receptor heteromerization and β‐arrestin‐scaffolded signalosomes that facilitate dynamic crosstalk and emergent responses such as bistable apoptotic switches and context specific modulation of Gᵢ/o, Gₛ/olf, and Gq pathways. We detail molecular mechanisms underpinning ETS behavior, including lipid mediated allostery, scaffold protein recruitment, and lateral diffusion effects, and highlight the gut microbiota as pivotal architects of the eTBome through terpene synthase‐driven production of bioactive ligands. Germ free and antibiotic treated animal models underscore the dependence of ETS ligand pools and receptor distributions on microbial colonization. This article proposes key avenues for experimental validation, including high resolution structural studies of CB‐OR heteromers, quantitative lipidomic mapping of eTBome distributions, live cell super resolution imaging of receptor nanoclusters, and gnotobiotic manipulations of microbial terpene synthesis. By introducing them as proposals to the scientific community and by integrating ECS/eCBome biology with olfactory receptor (OR) and microbial metabolite research, the ETS/eTBome concept offers a cohesive hypothesis for lipid‐driven GPCR crosstalk and indicated non‐standard targets for therapeutic modulation in cancer, neuroinflammation, and metabolic disorders.
- Open Access
- 21 April 2026
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine Open
- Vol. 3 (2)
Comparison of 166Holmium and 90Yttrium TARE in Hepatocellular Carcinoma Treatment
Transarterial radioembolization (TARE) is widely used as an effective and safe local treatment option, especially in patients with intermediate and advanced hepatocellular carcinoma. Yttrium-90 ( 90 Y) microspheres, which have been used as the standard radioisotope for many years, enable the delivery of high doses of radiation to tumor tissue due to their pure β-emission properties. Holmium-166 ( 166 Ho) microspheres, on the other hand, offer the advantage of direct visualization via SPECT and magnetic resonance imaging (MRI), in addition to β-radiation, due to their γ-photon emission and paramagnetic properties. These features enable personalized dosimetry before and after treatment and provide more accurate predictions in treatment planning.
- 21 April 2026
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine Open
- Vol. 3 (2)
Open AccessComparison of 166Holmium and 90Yttrium TARE in Hepatocellular Carcinoma Treatment
Transarterial radioembolization (TARE) is widely used as an effective and safe local treatment option, especially in patients with intermediate and advanced hepatocellular carcinoma. Yttrium-90 ( 90 Y) microspheres, which have been used as the standard radioisotope for many years, enable the delivery of high doses of radiation to tumor tissue due to their pure β-emission properties. Holmium-166 ( 166 Ho) microspheres, on the other hand, offer the advantage of direct visualization via SPECT and magnetic resonance imaging (MRI), in addition to β-radiation, due to their γ-photon emission and paramagnetic properties. These features enable personalized dosimetry before and after treatment and provide more accurate predictions in treatment planning.
- Open Access
- 23 January 2026
- Published by Springer Nature in Apoptosis
- Vol. 31 (2) , 56
Enhancing the efficacy of VEGF inhibitors by co-inhibition of HIF in the treatment of glioblastoma
Glioblastoma is the most aggressive and most common grade 4 tumor of the central nervous system (CNS). Despite standard treatments such as surgical resection and chemoradiotherapy, overall survival (OS) usually does not exceed 14–16 months in clinical trials, and no improvement in OS has been demonstrated even with the use of vascular endothelial growth factor A (VEGFA) inhibitors such as bevacizumab. In response to radiotherapy, hypoxia-inducible factor (HIF) stabilization leads to activation of alternative pro-angiogenic pathways, increasing VEGF expression and tumor angiogenesis. Several clinical trials evaluating HIF-2α inhibitors as monotherapy in the absence of concurrent VEGF inhibition, have similarly failed to demonstrate a significant improvement in OS outcomes. This review provides a perspective on the combined use of VEGF and HIF inhibitors, and provides an insight into future studies.
- 23 January 2026
- Published by Springer Nature in Apoptosis
- Vol. 31 (2) , 56
Open AccessEnhancing the efficacy of VEGF inhibitors by co-inhibition of HIF in the treatment of glioblastoma
Glioblastoma is the most aggressive and most common grade 4 tumor of the central nervous system (CNS). Despite standard treatments such as surgical resection and chemoradiotherapy, overall survival (OS) usually does not exceed 14–16 months in clinical trials, and no improvement in OS has been demonstrated even with the use of vascular endothelial growth factor A (VEGFA) inhibitors such as bevacizumab. In response to radiotherapy, hypoxia-inducible factor (HIF) stabilization leads to activation of alternative pro-angiogenic pathways, increasing VEGF expression and tumor angiogenesis. Several clinical trials evaluating HIF-2α inhibitors as monotherapy in the absence of concurrent VEGF inhibition, have similarly failed to demonstrate a significant improvement in OS outcomes. This review provides a perspective on the combined use of VEGF and HIF inhibitors, and provides an insight into future studies.
- 1 August 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2500518
Use of Protein Arginine Methyltransferase Inhibitors in Gliomas
Gliomas are a type of CNS tumors. Protein arginine methyltransferases (PRMTs) play important epigenetic regulatory roles in various cancers, including gliomas, by regulating DNA repair and cellular signaling pathways. Recent studies have also identified overexpression of PRMTs in gliomas and have shown that it is associated with tumor progression and resistance to conventional therapies. Targeting PRMTs has shown promising preclinical results demonstrating the potential to disrupt tumor growth, enhance DNA damage responses, and improve the sensitivity of gliomas to radiotherapy and temozolomide. In this review, we focus on the translational and clinical relevance of PRMT inhibitors in glioma subtypes, highlighting their latest clinical developments and ongoing clinical trials. Unlike previous reviews, our article provides an updated synthesis of clinical data, discusses challenges and opportunities in clinical translation, and suggests future directions for integrating PRMT inhibitors into glioma therapy.
- 1 August 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2500518
Use of Protein Arginine Methyltransferase Inhibitors in Gliomas
Gliomas are a type of CNS tumors. Protein arginine methyltransferases (PRMTs) play important epigenetic regulatory roles in various cancers, including gliomas, by regulating DNA repair and cellular signaling pathways. Recent studies have also identified overexpression of PRMTs in gliomas and have shown that it is associated with tumor progression and resistance to conventional therapies. Targeting PRMTs has shown promising preclinical results demonstrating the potential to disrupt tumor growth, enhance DNA damage responses, and improve the sensitivity of gliomas to radiotherapy and temozolomide. In this review, we focus on the translational and clinical relevance of PRMT inhibitors in glioma subtypes, highlighting their latest clinical developments and ongoing clinical trials. Unlike previous reviews, our article provides an updated synthesis of clinical data, discusses challenges and opportunities in clinical translation, and suggests future directions for integrating PRMT inhibitors into glioma therapy.
- 29 July 2025
- Published by Springer Nature in Neurochemical Research
- Vol. 50 (4) , 254
Intranasal Terpene Treatment for Glioblastoma: the Neuro-Oncological Potential of Perillyl Alcohol
Glioblastoma is the most aggressive and fatal primary brain tumor in adults, characterized by poor prognosis and limited treatment efficacy due to the impermeability of the blood-brain barrier (BBB) and its treatment-resistant nature. This review aims to evaluate the potential of intranasal terpene treatment (ITT) as a novel and non-invasive strategy to bypass the BBB and improve glioblastoma treatment outcomes. A review of recent preclinical and clinical studies on intranasally administered compounds (especially terpenes such as Perillyl alcohol (POH)) is presented in terms of their molecular mechanisms, bioavailability, and clinical effects in the central nervous system (CNS).
- 29 July 2025
- Published by Springer Nature in Neurochemical Research
- Vol. 50 (4) , 254
Intranasal Terpene Treatment for Glioblastoma: the Neuro-Oncological Potential of Perillyl Alcohol
Glioblastoma is the most aggressive and fatal primary brain tumor in adults, characterized by poor prognosis and limited treatment efficacy due to the impermeability of the blood-brain barrier (BBB) and its treatment-resistant nature. This review aims to evaluate the potential of intranasal terpene treatment (ITT) as a novel and non-invasive strategy to bypass the BBB and improve glioblastoma treatment outcomes. A review of recent preclinical and clinical studies on intranasally administered compounds (especially terpenes such as Perillyl alcohol (POH)) is presented in terms of their molecular mechanisms, bioavailability, and clinical effects in the central nervous system (CNS).
- 17 March 2025
- Published by Springer Nature in Molecular Neurobiology
- Vol. 62 (7) , 9170-9174
Potential Risks of Minoxidil in Pheochromocytoma and Paraganglioma: A Commentary on Safety Concerns and Mechanisms
Pheochromocytoma and paraganglioma are neuroendocrine tumours characterised by excessive catecholamine release. Minoxidil, a potent vasodilator commonly used for hypertension and androgenetic alopecia, may exacerbate cardiovascular complications associated with pheochromocytoma due to its mechanisms-of-action. This commentary aims to elucidate the potential risks and safety concerns associated with the use of minoxidil in patients with pheochromocytoma. Here, we discuss the need for careful prescribing practices when considering minoxidil in pheochromocytoma-associated hypertension and the potential problems that minoxidil use may cause in pheochromocytoma patients.
- 17 March 2025
- Published by Springer Nature in Molecular Neurobiology
- Vol. 62 (7) , 9170-9174
Potential Risks of Minoxidil in Pheochromocytoma and Paraganglioma: A Commentary on Safety Concerns and Mechanisms
Pheochromocytoma and paraganglioma are neuroendocrine tumours characterised by excessive catecholamine release. Minoxidil, a potent vasodilator commonly used for hypertension and androgenetic alopecia, may exacerbate cardiovascular complications associated with pheochromocytoma due to its mechanisms-of-action. This commentary aims to elucidate the potential risks and safety concerns associated with the use of minoxidil in patients with pheochromocytoma. Here, we discuss the need for careful prescribing practices when considering minoxidil in pheochromocytoma-associated hypertension and the potential problems that minoxidil use may cause in pheochromocytoma patients.
- 5 March 2025
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 37 (8) , e70017
Nuclear medicine and perspective thoughts in the diagnosis and treatment of pheochromocytoma and paraganglioma
Pheochromocytoma and paraganglioma (PPGL) are rare and life‐threatening tumors of the adrenal medulla and extra‐adrenal paraganglia, respectively. Management of PPGL depends on accurate diagnosis and treatment. This review provides a very comprehensive overview of nuclear medicine in PPGL with some of our perspective views on diagnostic challenges and pitfalls, treatment, and new phase studies. It describes nuclear medicine techniques including 64Cu/68Ga‐DOTA‐SSA, 18F‐FDOPA, 18F‐FDG, 123I‐MIBG, and some emerging molecular imaging agents and PRRT therapies, such as 203Pb VMT‐α‐NET and 212Pb VMT‐α‐NET targeted alpha therapy (TAT). It also provides insight into the use of proliferating cell nuclear antigen (PCNA) inhibitors in combination with therapeutics in aggressive/metastatic PPGL. Through a comprehensive review of the latest developments and clinical practice, this review aims to guide healthcare professionals in improving the diagnostic accuracy and therapeutic efficacy of PPGL.
- 5 March 2025
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 37 (8) , e70017
Nuclear medicine and perspective thoughts in the diagnosis and treatment of pheochromocytoma and paraganglioma
Pheochromocytoma and paraganglioma (PPGL) are rare and life‐threatening tumors of the adrenal medulla and extra‐adrenal paraganglia, respectively. Management of PPGL depends on accurate diagnosis and treatment. This review provides a very comprehensive overview of nuclear medicine in PPGL with some of our perspective views on diagnostic challenges and pitfalls, treatment, and new phase studies. It describes nuclear medicine techniques including 64Cu/68Ga‐DOTA‐SSA, 18F‐FDOPA, 18F‐FDG, 123I‐MIBG, and some emerging molecular imaging agents and PRRT therapies, such as 203Pb VMT‐α‐NET and 212Pb VMT‐α‐NET targeted alpha therapy (TAT). It also provides insight into the use of proliferating cell nuclear antigen (PCNA) inhibitors in combination with therapeutics in aggressive/metastatic PPGL. Through a comprehensive review of the latest developments and clinical practice, this review aims to guide healthcare professionals in improving the diagnostic accuracy and therapeutic efficacy of PPGL.
- 5 March 2025
- Published by Springer Nature in Molecular Biology Reports
- Vol. 52 (1) , 1-9
Von Hippel-Lindau syndrome: clinical features, genetic foundations, and management strategies
Von Hippel-Lindau Syndrome (VHL) is a rare, hereditary disorder characterized by the development of multiple tumors and cysts in various parts of the body due to mutations in the VHL gene on chromosome 3p25-26. Patients with VHL are at increased risk for hemangioblastomas of the brain, spinal cord, and retina, renal cell carcinomas, pheochromocytomas, pancreatic neuroendocrine tumors, and endolymphatic sac tumors. Clinical manifestations vary widely, and early diagnosis through genetic testing and regular surveillance is crucial for effective management. Treatment involves monitoring for tumor development, surgical removal of tumors, and targeted therapies for advanced cases. Recent advances in understanding the VHL pathway have led to new targeted treatments, particularly those involving the hypoxia-inducible factors and vascular endothelial growth factor pathways, which have improved patient outcomes. This article reviews the clinical features, genetic foundations, genotype/phenotype relationship and current management strategies for VHL, emphasizing recent advances that have enhanced prognosis and quality of life for patients.
- 5 March 2025
- Published by Springer Nature in Molecular Biology Reports
- Vol. 52 (1) , 1-9
Von Hippel-Lindau syndrome: clinical features, genetic foundations, and management strategies
Von Hippel-Lindau Syndrome (VHL) is a rare, hereditary disorder characterized by the development of multiple tumors and cysts in various parts of the body due to mutations in the VHL gene on chromosome 3p25-26. Patients with VHL are at increased risk for hemangioblastomas of the brain, spinal cord, and retina, renal cell carcinomas, pheochromocytomas, pancreatic neuroendocrine tumors, and endolymphatic sac tumors. Clinical manifestations vary widely, and early diagnosis through genetic testing and regular surveillance is crucial for effective management. Treatment involves monitoring for tumor development, surgical removal of tumors, and targeted therapies for advanced cases. Recent advances in understanding the VHL pathway have led to new targeted treatments, particularly those involving the hypoxia-inducible factors and vascular endothelial growth factor pathways, which have improved patient outcomes. This article reviews the clinical features, genetic foundations, genotype/phenotype relationship and current management strategies for VHL, emphasizing recent advances that have enhanced prognosis and quality of life for patients.
- 10 December 2024
- Published by Springer Nature in Cellular Oncology
- Vol. 47 (6) , 2091-2098
Role of BRCA1 in glioblastoma etiology
BRCA1 (Breast Cancer 1) is a tumor suppressor gene with a role in DNA repair by Homologous Recombination (HR), and maintenance of genomic stability that is frequently investigated in breast, prostate, and ovarian cancers. BRCA1 mutations or dysregulation in glioblastoma can lead to impaired DNA repair mechanisms, resulting in tumor progression and resistance to standard therapies. Several studies have shown that BRCA1 expression is altered, albeit rarely, in glioblastoma, leading to poor prognosis and increased tumor aggressiveness. In addition, the communication of BRCA1 with other molecular pathways such as p53 and PTEN further complicates its role in glioblastoma pathogenesis. Targeting BRCA1-related pathways in these cases has shown the potential to improve the efficacy of standard treatments, including radiotherapy and chemotherapy. The development of (Poly (ADP-ribose) Polymerase) PARP inhibitors that exploit the lack of HR also offers a therapeutic approach to glioblastoma patients with BRCA1 mutations. Despite these advances, the heterogeneity of glioblastoma and its complex tumor microenvironment make the translation of such approaches into clinical practice still challenging, and there is an “unmet need”. This review discusses the current mechanisms of etiology and potential treatment of BRCA1-related glioblastoma.
- 10 December 2024
- Published by Springer Nature in Cellular Oncology
- Vol. 47 (6) , 2091-2098
Role of BRCA1 in glioblastoma etiology
BRCA1 (Breast Cancer 1) is a tumor suppressor gene with a role in DNA repair by Homologous Recombination (HR), and maintenance of genomic stability that is frequently investigated in breast, prostate, and ovarian cancers. BRCA1 mutations or dysregulation in glioblastoma can lead to impaired DNA repair mechanisms, resulting in tumor progression and resistance to standard therapies. Several studies have shown that BRCA1 expression is altered, albeit rarely, in glioblastoma, leading to poor prognosis and increased tumor aggressiveness. In addition, the communication of BRCA1 with other molecular pathways such as p53 and PTEN further complicates its role in glioblastoma pathogenesis. Targeting BRCA1-related pathways in these cases has shown the potential to improve the efficacy of standard treatments, including radiotherapy and chemotherapy. The development of (Poly (ADP-ribose) Polymerase) PARP inhibitors that exploit the lack of HR also offers a therapeutic approach to glioblastoma patients with BRCA1 mutations. Despite these advances, the heterogeneity of glioblastoma and its complex tumor microenvironment make the translation of such approaches into clinical practice still challenging, and there is an “unmet need”. This review discusses the current mechanisms of etiology and potential treatment of BRCA1-related glioblastoma.